Renal-Cell Carcinoma

Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma

Chase Doyle

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Renal-Cell Carcinoma

Chicago, IL—The results of a phase 3 clinical trial support the use of avelu­mab (Bavencio) plus axitinib (Inlyta) as a new first-line standard-of-care treatment for patients with newly diagnosed advanced renal-cell carcinoma. According to data presented at ASCO 2019, JAVELIN Renal 101 demonstrated longer progression-free survival (PFS) and higher overall response rates for the combination of avelumab with axitinib versus sunitinib (Sutent) monotherapy for treatment-naïve patients with advanced renal-cell carcinoma. The benefit was not limited only to the first-line setting. Patients who received avelumab plus axitinib also had longer PFS after second-line treatment and a longer mean duration of response than patients who received sunitinib alone. [ Read More ]

Cabozantinib a New First-Line Standard Therapy for High-Risk Advanced Renal-Cell Carcinoma?

Charles Bankhead

November 2016, Vol 7, No 10 - Renal-Cell Carcinoma

Copenhagen, Denmark—The current standard for the first-line targeted treatment of metastatic renal-cell carcinoma (RCC) came out on the short end of a randomized comparison with the new multikinase inhibitor cabozantinib (Cabometyx), according to results reported at the 2016 European Society for Medical Oncology Congress. [ Read More ]

Adjuvant Sunitinib Therapy Improves Outcomes in Clear-Cell Renal-Cell Carcinoma

Phoebe Starr

November 2016, Vol 7, No 10 - Renal-Cell Carcinoma

Copenhagen, Denmark—For the first time, a randomized clinical trial has shown that adjuvant therapy improves outcomes in patients with clear-cell renal-cell carcinoma (RCC). Adjuvant treatment with sunitinib (Sutent) improved disease-free survival (DFS) by >1 year in patients with high-risk locoregional RCC after nephrectomy, according to results from the S-TRAC clinical trial. Although this is encouraging news, at the 2016 European Society for Medical Oncology Congress some experts noted they were not ready to adopt it as a new standard of care, because of the associated toxicity and lack of an overall survival benefit. [ Read More ]